Cellatoz Therapeutics, Inc., a South Korean biotech venture company specializing in cell therapy drug
development, has commenced the first patient enrollment in the Phase 1 clinical trial of their peripheral
neuropathy treatment (code name: CLZ-2002) at Samsung Seoul Hospital on July 10th. The trial aims to
evaluate the safety, maximum tolerated dose, and potential therapeutic effects of CLZ-2002 in patients
with Charcot-Marie-Tooth Type 1 (CMT1).